Mobile website
Preparation of Gastric Cancer Specific Nanovaccine and Study of Its Immunocompetence
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To develop a peptide vaccine based on MG7-Ag mimotope of gastric cancer using new nano-technology and valuate its efficacy and protective effect. Methods:Encapsulate synthesized MG7 mimotope peptide into nanoemulsion using magnetic and ultrasonic technique. Dialyse method was used to sterilize, HPLC to determine encapsulation efficiency. Select CpG motif as immune adjuvant, Balb/c mice were immunized intravenously with MG7 nanovaccine , with empty nanoemulsion and phosphate buffered saline (PBS) as control. Serum titer of MG7 antibody was determined by ELISA assay. ELISPOT was performed to test the cytotoxicity of spleen cells. The protective effect of the nanovaccine was evaluated by tumor cell challenge assay.Results: G7 nanovaccine was successfully constructed with high stability and encapsulation efficiency. It could induce both cellular and humour immune response to MG7-Ag in mice. Tumor cell challenge shown that the tumor masses formed in the mice immunized with nanovaccine markedly smaller than those formed in the mice of control groups. 2 out of 8 immunized mice were tumor free, while none in the control groups was protected. Conclusion: Nanovaccine based on the MG7-Ag mimotope is immunogenic which can induce specific immunity response against tumor in mice. And the vaccine is partially protective.
Keywords:
Project Supported:
Clc Number:
R737.11
